Lymphoma Treatment Market Report by Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), Test Type (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Biologic Therapy, and Others), Drug (Adcetris, Rituxan, Opdivo, Imbruvica, Keytruda, Revlimid, and Others), and Region 2024-2032

Lymphoma Treatment Market Report by Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), Test Type (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Biologic Therapy, and Others), Drug (Adcetris, Rituxan, Opdivo, Imbruvica, Keytruda, Revlimid, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A3385
Buy Now

Global Lymphoma Treatment Market:

The global lymphoma treatment market size reached US$ 13.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 26.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032. The rising advancements in treatment modalities, increasing incidence of lymphoma, surging healthcare expenditure, and ongoing technological innovations are primarily driving the market's growth.

Report Attribute
Key Statistics
Base Year
2023
Forecast Years
2024-2032
Historical Years
2018-2023
Market Size in 2023 US$ 13.3 Billion
Market Forecast in 2032 US$ 26.0 Billion
Market Growth Rate (2024-2032) 7.5%


Lymphoma Treatment Market Analysis:

  • Major Market Drivers: The increasing prevalence of non-Hodgkin lymphoma across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, who are more susceptible to such ailments, is also driving the market growth.
  • Key Market Trends: The increasing awareness among the masses regarding the available diagnostic technologies and treatment alternatives for lymphoma is creating a positive outlook for the market. Additionally, various technological advancements, including the development of innovative immune checkpoint inhibitors, which block proteins from binding together and increase the response strength of T-cells against cancer cells, are contributing to the market growth.
  • Competitive Landscape: Some of the prominent lymphoma treatment market companies include Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd., among many others.
  • Geographical Trends: According to the lymphoma treatment market dynamics, North America represents a significant portion of the global lymphoma treatment market. This region benefits from advanced healthcare infrastructure, high healthcare spending, and access to cutting-edge therapies. Moreover, Europe has a robust market for lymphoma treatments, driven by strong healthcare systems and increasing access to novel therapies.
  • Challenges and Opportunities: High costs associated with advanced therapies, and lack of awareness among patients are hampering the market's growth. However, continued research and development of targeted therapies that specifically address cancer cells while minimizing damage to healthy cells offer promising avenues for effective lymphoma treatment.
     

Lymphoma Treatment Market Report


Lymphoma Treatment Market Trends:

Rising Prevalence of Lymphoma

The prevalence of lymphoma, including both Hodgkin and non-Hodgkin lymphoma, is rising globally due to factors like aging populations and improved diagnostic capabilities. For instance, according to the American Cancer Society, nearly 80,000 people will suffer from non-Hodgkin lymphoma in 2024. This further drives the demand for efficient treatment, further expected to propel the lymphoma treatment market in the coming years.

Surging Focus on Personalized Medicine

The rising focus on personalized medicine is significantly driving growth in the lymphoma treatment market. For instance, according to IMARC, the global precision medicine market size reached US$ 75.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 168.3 Billion by 2032, exhibiting a growth rate (CAGR) of 9.1% during 2024-2032. Personalized medicine in lymphoma treatment involves tailoring therapies based on individual patient characteristics, including genetic, molecular, and immunological profiles. These factors further positively influence the lymphoma treatment market forecast.

Increasing R&D Investments

Significant investments in R&D by pharmaceutical companies and research institutions drive the development of new and improved lymphoma treatments, expanding the market with innovative therapies. For instance, in November 2023, the Leukemia & Lymphoma Society (LLS), a private supporter of blood cancer research, granted $65 million in new awards to 78 research teams in seven countries. Moreover, ongoing clinical trials and research studies contribute to the advancement of treatment options and the introduction of novel therapies to the market, thereby boosting the lymphoma treatment market revenue.

Global Lymphoma Treatment Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global lymphoma treatment market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on type, test type, and drug.

Breakup by Type:

Lymphoma Treatment Market Report

  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
     

The report has provided a detailed breakup and analysis of the lymphoma treatment market based on the type. This includes Hodgkin lymphoma, and non-Hodgkin lymphoma.

According to the lymphoma treatment market outlook, Hodgkin lymphoma comprises a smaller proportion of all lymphomas, accounting for approximately 10% of cases worldwide. Moreover, it is more prevalent in developed countries compared to developing regions. Moreover, non-Hodgkin lymphoma is more common than Hodgkin lymphoma, accounting for approximately 90% of all lymphoma cases globally. NHL incidence rates have been increasing over the past few decades.

Breakup by Test Type:

  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy
  • Biologic Therapy
  • Others
     

The report has provided a detailed breakup and analysis of the lymphoma treatment market based on the test type. This includes chemotherapy, radiation therapy, immunotherapy, targeted therapy, biologic therapy, and others.

According to the lymphoma treatment market overview, chemotherapy involves the use of drugs to kill cancer cells or slow their growth. These drugs can be administered orally or intravenously and work by targeting rapidly dividing cells throughout the body. Moreover, radiation therapy uses high-energy beams to target and destroy cancer cells. It is often delivered externally (external beam radiation) or internally (brachytherapy). Apart from this, immunotherapy harnesses the power of the immune system to recognize and attack cancer cells. Key approaches include monoclonal antibodies and immune checkpoint inhibitors.

Breakup by Drug:

  • Adcetris
  • Rituxan
  • Opdivo
  • Imbruvica
  • Keytruda
  • Revlimid
  • Others
     

A detailed breakup and analysis of the lymphoma treatment market based on the drug has also been provided in the report. This includes Adcetris, Rituxan, Opdivo, Imbruvica, Keytruda, Revlimid, and others.

Adcetris is primarily used for the treatment of Hodgkin lymphoma (HL) and certain types of non-Hodgkin lymphoma (NHL), such as systemic anaplastic large cell lymphoma (sALCL). Moreover, Rituxan is a monoclonal antibody targeting CD20 antigen primarily used in B-cell NHL and certain autoimmune diseases like rheumatoid arthritis. Apart from this, Opdivo is an immune checkpoint inhibitor targeting PD-1 receptor used in various cancers, including melanoma, lung cancer, and Hodgkin lymphoma.

Breakup by Region:

Lymphoma Treatment Market Report

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

According to the lymphoma treatment market statistics, North America represents a significant portion of the global lymphoma treatment market owing to the higher prevalence of lymphoma, particularly non-Hodgkin lymphoma (NHL), due to factors like aging population and environmental exposures. Moreover, the increasing emphasis on genomic profiling and targeted therapies, is driving the market growth in Europe. Apart from this, the rising incidence of lymphoma in Asia Pacific, partly due to aging populations, urbanization, and changing lifestyles is supporting the industry's demand.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include: 

  • Abbott Laboratories
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
     

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Lymphoma Treatment Market Recent Developments:

  • February 2024: Knight Therapeutics Inc., a Pan-American specialty pharmaceutical company, launched the Minjuvi (tafasitamab) by its Brazilian affiliate for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
  • March 2024: GenFleet Therapeutics collaborated with BeiGene Switzerland to start a Phase Ib/II clinical trial with GFH009 and BRUKINSA (zanubrutinib) for the treatment of diffuse large B cell lymphoma.
  • November 2023: The Leukemia & Lymphoma Society (LLS), a private supporter of blood cancer research, granted $65 million in new awards to 78 research teams in seven countries.


Lymphoma Treatment Market Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion

Scope of the Report 

Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
  • Type
  • Test Type
  • Drug
  • Region
Types Covered Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Test Types Covered Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Biologic Therapy, Others
Drugs Covered Adcetris, Rituxan, Opdivo, Imbruvica, Keytruda, Revlimid, Others
Regions Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Key Questions Answered in This Report:

  • How has the global lymphoma treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global lymphoma treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the test type?
  • What is the breakup of the market based on the drug?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global lymphoma treatment market and who are the key players?
  • What is the degree of competition in the industry?


Key Benefits for Stakeholders:

  • IMARC's report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the lymphoma treatment market from 2018-2032.
  • The research study provides the latest information on the market drivers, challenges, and opportunities in the global lymphoma treatment market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the lymphoma treatment industry and its attractiveness.
  • The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market. 

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Lymphoma Treatment Market Report by Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), Test Type (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Biologic Therapy, and Others), Drug (Adcetris, Rituxan, Opdivo, Imbruvica, Keytruda, Revlimid, and Others), and Region 2024-2032
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARATI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More
DEinternational Egypt

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

Read More